ECOG-ACRIN Cancer Research Group

What ECOG-ACRIN Cancer Research Group does

ECOG-ACRIN Cancer Research Group is a Philadelphia-headquartered, membership-based non-profit scientific organization that designs and conducts biomarker-driven clinical and translational cancer research in adults. It operates as a member of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) and as a Research Base in the NCI Community Oncology Research Program (NCORP), coordinating trials across nearly 1,400 academic and community cancer centers, 67 international sites, and approximately 21,000 affiliated research professionals and advocates.

Its portfolio centers on major precision medicine and immunotherapy trials, including TAILORx, RxPONDER, NCI-MATCH, ComboMATCH, and myeloMATCH, supported by in-house research infrastructure such as the TRIAD imaging core lab, the Central Biorepository and Pathology Facility, a Sample Tracking System, the Leukemia and Thoracic Malignancies Integrated Translational Science Centers, and the ECOG Performance Status Scale as a standardized patient stratification tool. Clinical data is captured via Medidata Rave, and ethics review is handled through the NCI Central IRB. The group has begun layering AI capabilities on top of its data assets, including a multi-year collaboration with Caris Life Sciences to develop multimodal AI models for breast cancer recurrence risk stratification and survival prediction in advanced melanoma.

Funding flows primarily from NCI NCTN and NCORP grants as recurring appropriations, supplemented by Cooperative Research and Development Agreements with pharmaceutical sponsors (Bristol Myers Squibb, Novartis, Partner Therapeutics) that supply investigational agents and co-fund trials such as EA6141 in melanoma and DREAMseq (EA6134). Member institution dues provide an additional modest revenue stream. The organization has no product or service pricing; trials are conducted under research protocols rather than commercial contracts, and monetization is through grant-funded research output rather than fee-for-service.

Name

ECOG-ACRIN Cancer Research Group

Legal name

ECOG-ACRIN Cancer Research Group

Website

https://ecog-acrin.org

Company type

Private

Operating status

Operating

Short description

ECOG-ACRIN Cancer Research Group is a Philadelphia-based non-profit that designs and conducts biomarker-driven adult cancer clinical trials across roughly 1,400 sites as part of the NCI National Clinical Trials Network.

Ownership category

akta.pro rank

Product category

Clinical Cancer Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Clinical Trial Site Operations & Study Coordination (HLAGACAE)

Keywords

• Clinical trials research
• Biomarker-driven oncology
• Precision medicine trials
• Cancer research network
• Translational science research

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. NCI NCTN Funding: Primary funding from the National Cancer Institute through the National Clinical Trials Network (NCTN), supporting the design and conduct of biomarker-driven cancer clinical trials.
2. NCI NCORP Research Base Funding: Funding as a Research Base in the NCI Community Oncology Research Program (NCORP) for cancer control and outcomes research.
3. Pharmaceutical CRADA Collaborations: Cooperative Research and Development Agreements with pharmaceutical companies such as Bristol Myers Squibb (for nivolumab and ipilimumab) and Partner Therapeutics (for sargramostim) that provide drug supply and funding support for clinical trials.
4. Member Institution Dues: Membership dues from participating hospitals and cancer centers that contribute to the research network infrastructure.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels12 records

Core offering

ECOG-ACRIN Cancer Research Group is a membership-based non-profit scientific organization that designs and conducts biomarker-driven clinical and translational cancer research involving adults with or at risk of cancer. It operates a network of nearly 1,400 academic and community-based cancer centers, supporting major precision medicine trials such as TAILORx, RxPONDER, NCI-MATCH, ComboMATCH, and myeloMATCH, along with research cores for imaging, biorepository, leukemia, and thoracic malignancies.

Product overview

ECOG-ACRIN Cancer Research Group is a membership-based scientific organization that designs and conducts biomarker-driven clinical research involving adults who have or are at risk of developing cancer. The organization operates as a network of nearly 1,400 academic and community-based cancer centers with approximately 21,000 research professionals. ECOG-ACRIN's portfolio includes major precision medicine trials such as TAILORx, RxPONDER, NCI-MATCH, ComboMATCH, and myeloMATCH, along with research cores for imaging (TRIAD), biorepository/pathology services, leukemia research, and thoracic malignancies. The organization supports its research mission with infrastructure including Medidata Rave for clinical data management, Sample Tracking System, and the ECOG Performance Status Scale. Educational offerings include a YouTube-based Training Video Resource Library and mentorship awards including the Young Investigator Award, Paul Carbone Fellowship Award, and Remarkable Mentor in Oncology Award. Collaborative programs like PrE1702 generate real-world evidence for EGFR-mutated NSCLC, while the TAILORx/RxPONDER platform has evolved into a discovery engine using advanced tumor profiling and AI for breast cancer recurrence analysis.

Differentiator

Problem solved

Functional benefit

Brands

• NCI-MATCH: National Cancer Institute Molecular Analysis for Therapy Choice - a precision medicine trial
• ComboMATCH
• TAILORx
• TMIST
• PrECOG

Products and services

• TAILORx

Quantifiable outcome

• Smoking cessation doubled (28.4% vs 14.7%) with proactive telehealth counseling and nicotine replacement therapy in cancer patients
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Eleven partnerships are on record, tiered core, major, notable and supporting.

• National Cancer Institute (NCI)coreStrategic or Co-development PartnerPrimary funding partner through the National Clinical Trials Network (NCTN) and NCI Community Oncology Research Program (NCORP). NCI provides primary funding support for ECOG-ACRIN trials including EA6141 melanoma trial and E1910 blinatumomab trial.
• Alliance for Clinical Trials in OncologycoreStrategic or Co-development PartnerNCTN cooperative group partner collaborating on EA6141 melanoma trial enrollment alongside ECOG-ACRIN, NRG Oncology, and SWOG Cancer Research Network.
• NRG OncologycoreStrategic or Co-development PartnerNCTN cooperative group partner collaborating on EA6141 melanoma trial enrollment alongside ECOG-ACRIN, Alliance, and SWOG Cancer Research Network.
• SWOG Cancer Research NetworkcoreStrategic or Co-development PartnerNCTN cooperative group partner collaborating on EA6141 melanoma trial enrollment alongside ECOG-ACRIN, Alliance, and NRG Oncology.
• Bristol Myers SquibbmajorStrategic or Co-development PartnerSupplied nivolumab and ipilimumab through an NCI CRADA and provided funding support for EA6141 melanoma trial. Also provided support for DREAMseq trial through NCI collaborative agreement.
• Partner TherapeuticsmajorStrategic or Co-development PartnerSupplied sargramostim through an NCI CRADA for the EA6141 melanoma trial.
• PrECOG, LLCmajorStrategic or Co-development PartnerAffiliate research organization collaborating on blood cancer research including PrE0405 bendamustine/rituximab/venetoclax trial for mantle cell lymphoma and PrE1702 lung cancer real-world data study.
• Caris Life SciencesmajorTechnology or IntegrationMulti-year collaboration to advance AI-powered multimodal tools for breast cancer recurrence risk stratification using advanced tumor profiling and AI developed by ECOG-ACRIN and Caris.
• Novartis PharmaceuticalsmajorStrategic or Co-development PartnerProvided dabrafenib and trametinib through NCI Cooperative Research and Development Agreements for DREAMseq melanoma trial.
• Providence Cancer Institute / Earle A. Chiles Research InstitutenotableStrategic or Co-development PartnerParticipating member institution with Dr. Natasha Edwin serving as community co-chair of ECOG-ACRIN Myeloma Committee, bringing rural community perspective to trial design.
• Medidata (Dassault Systèmes)supportingTechnology or IntegrationProvides Medidata Rave electronic data capture system used by ECOG-ACRIN for clinical trial data management.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• IQVIA: Largest global commercial CRO offering comprehensive clinical trial services across all therapeutic areas including oncology. Competes with ECOG-ACRIN for pharma-sponsored oncology trial execution at a much larger scale.
• National Cancer Institute (NCI): Federal sponsor of the NCTN and primary funder of ECOG-ACRIN. While not a commercial peer, NCI sets the strategic direction for cancer clinical trials in the U.S. and directly influences ECOG-ACRIN's research priorities and funding.

Regional players

• Cancer Research UK: Largest cancer research charity in the UK that funds and conducts clinical and translational cancer research. Comparable non-profit model focused on cancer trials and precision oncology but operating primarily in the UK.
• European Organisation for Research and Treatment of Cancer (EORTC): Europe's leading cooperative group running multi-center cancer clinical trials. Comparable mission and structure to ECOG-ACRIN but serves primarily European sites; relevant when sponsors seek transatlantic trial partnerships.

Direct peers

• NRG Oncology: NCI NCTN cooperative group formed from the integration of NSABP, RTOG, and GOG, focused on cancer clinical trials. Competes with ECOG-ACRIN for NCTN leadership and jointly enrolls patients on trials such as EA6141 melanoma.
• Alliance for Clinical Trials in Oncology: NCI-funded cooperative group conducting adult cancer clinical trials across a similar multi-institutional network. Directly comparable to ECOG-ACRIN in mission, NCI funding model, and trial portfolio, including co-enrollment on phase 2/3 melanoma studies.
• SWOG Cancer Research Network: One of the four NCI NCTN cooperative groups that designs and conducts multi-site cancer clinical trials. Co-enrolls with ECOG-ACRIN on trials like EA6141 and competes for the same NCI sponsorship and pharma CRADA opportunities in oncology.

Emerging players

• Caris Life Sciences: AI-driven molecular profiling and precision medicine company collaborating with ECOG-ACRIN on breast cancer recurrence risk models. Comparable in the precision oncology/AI space but commercial rather than cooperative-group based.

Others

• PrECOG, LLC: Affiliate research subsidiary of ECOG-ACRIN focused on blood cancer and real-world evidence studies. Not a true peer but an adjacent operating entity that uses similar trial infrastructure and investigator networks.
• Medidata (Dassault Systèmes): Provider of the Medidata Rave electronic data capture platform used by ECOG-ACRIN for clinical trial data management. Not a peer in research but a key enabling technology partner whose platform underpins ECOG-ACRIN's trial operations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/eaonc
• YouTubeyoutube.com/@ecog-acrin
• Facebookfacebook.com/eaonc
• LinkedInlinkedin.com/company/ecog-acrin-cancer-research-group
• Instagraminstagram.com/ecog_acrin

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ECOG-ACRIN Cancer Research Group